Skip to main content
Cardiolucent

Treatment

Antiplatelet Therapy (Aspirin, Clopidogrel)

Targeted platelet inhibition to prevent heart attack and stent thrombosis.

Antiplatelet medications reduce the ability of platelets to aggregate and form clots in arteries, which is the mechanism behind most heart attacks and ischemic strokes. The two most commonly used agents are aspirin (a COX-1 inhibitor) and the P2Y12 inhibitors — clopidogrel, ticagrelor, and prasugrel. Single antiplatelet therapy is standard for many patients with established cardiovascular disease, while dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) is required after stent placement or acute coronary syndrome for a defined period. Dr. Kedan tailors agent selection and duration to your specific risk profile, prior procedures, and bleeding considerations.

What This Treatment Approach Includes

  • Indication-specific decision: primary prevention vs secondary prevention vs post-stent
  • Selection between aspirin, clopidogrel, ticagrelor, and prasugrel based on scenario
  • Duration planning for dual antiplatelet therapy after stenting or acute coronary syndrome
  • Bleeding risk assessment and gastrointestinal protection when warranted
  • Periprocedural management — when to hold, when to bridge, when to resume
  • Coordination with anticoagulation when both are required ("triple therapy" decisions)
  • Surveillance for bleeding and reevaluation as risk profile changes

How It Works

Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets, blocking thromboxane A2 production and reducing platelet aggregation for the lifespan of the platelet (about 7 to 10 days). P2Y12 inhibitors block the adenosine diphosphate receptor on the platelet surface, preventing the conformational change required for stable platelet activation. Combining the two classes (DAPT) provides additive inhibition during the period when arterial healing or stent endothelialization is most vulnerable to thrombosis.

Who This Is For

  • Established coronary artery disease, prior heart attack, or prior coronary intervention
  • Ischemic stroke or transient ischemic attack of atherothrombotic origin
  • Peripheral artery disease with symptoms or prior revascularization
  • After coronary stenting — required dual antiplatelet therapy for a defined period
  • Acute coronary syndrome treated medically or with PCI
  • Selected high-risk primary prevention scenarios after careful risk-benefit discussion
  • Carotid disease following revascularization

Monitoring and Follow-Up

Antiplatelet therapy does not require routine laboratory monitoring, but ongoing assessment focuses on bleeding signs, drug interactions, and changes in risk profile that might shift the duration plan. After stenting or acute coronary syndrome, the duration of dual therapy is decided in advance and revisited at scheduled intervals — sometimes shortened for bleeding risk, sometimes extended for ongoing ischemic risk. Direct access to Dr. Kedan allows real-time decisions when surgery, dental work, or new bleeding arises.

How Cardiolucent Manages This

Antiplatelet duration after stenting and acute coronary syndrome is one of the most frequent points of confusion when care is fragmented between cardiology, primary care, and proceduralists. Dr. Kedan personally tracks the indication, the start date, the planned duration, and the post-DAPT plan — and coordinates with your surgeon when procedures arise mid-course. Extended visits also allow shared decision-making about bleeding risk and protective strategies when both antiplatelet and anticoagulant therapy are required.

Common Questions

Frequently Asked Questions

Why do I need an antiplatelet medication?
Antiplatelet drugs prevent platelets from sticking together and forming clots in arteries, which is the mechanism behind most heart attacks and ischemic strokes. They are used for secondary prevention after established cardiovascular events or procedures, and selectively for primary prevention in high-risk patients.
Is aspirin still recommended for primary prevention?
The guidance has shifted. Routine aspirin for primary prevention in healthy older adults is no longer recommended because bleeding risk often exceeds clotting benefit. For selected higher-risk patients without prior events, an individualized conversation about risk and benefit may justify low-dose aspirin. Dr. Kedan applies the calculation to your specific profile.
What is dual antiplatelet therapy (DAPT) and how long does it last?
DAPT combines aspirin with a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) and is required for a defined period after coronary stent placement or acute coronary syndrome. The standard duration is typically several months to a year, but can be shorter for bleeding risk or longer for ongoing ischemic risk. The plan is set at the time of stenting and revisited along the way.
What is the difference between clopidogrel, ticagrelor, and prasugrel?
All three block the P2Y12 receptor but differ in onset, potency, and reversibility. Ticagrelor and prasugrel are more potent and faster-acting than clopidogrel, with a stronger ischemic-protection effect but also higher bleeding risk. Clopidogrel is well-established and lower-cost. The choice depends on the clinical scenario, prior bleeding, age, and other factors.
What about combining antiplatelet and anticoagulant therapy?
Some patients — particularly those with atrial fibrillation who also undergo coronary stenting — temporarily need both antiplatelet and anticoagulant therapy. The combination significantly increases bleeding risk, so modern strategies aim to minimize the duration of triple therapy and transition to a regimen with fewer agents as soon as safely possible. Dr. Kedan coordinates this carefully with the interventional team.
What bleeding signs should I take seriously?
Major bleeding signs requiring urgent attention include blood in the urine or stool (including black, tarry stools), coughing or vomiting blood, severe headache or vision changes, prolonged nosebleeds, and any significant trauma — particularly head trauma. Easy bruising and minor gum bleeding are common and usually not dangerous, but worsening patterns warrant a conversation.
What about surgery or dental work?
Periprocedural management depends on bleeding risk of the procedure and the ischemic risk of holding therapy. Most minor dental work does not require holding aspirin or clopidogrel; major surgery often does. After recent stent placement, holding DAPT carries serious risk of stent thrombosis and is coordinated very carefully. Always notify Dr. Kedan and your surgeon as soon as a procedure is scheduled.
Do these drugs interact with anything?
Aspirin and P2Y12 inhibitors interact with other antithrombotics (additive bleeding), NSAIDs, certain antidepressants (additive bleeding effect), and some proton pump inhibitors may reduce clopidogrel activity. Disclose every medication and supplement, including over-the-counter products, at every visit.
Can I stop antiplatelet therapy if I feel fine?
No — these medications work because they are taken continuously. Stopping aspirin or a P2Y12 inhibitor without coordinated planning, especially after recent stent placement, sharply increases the risk of a heart attack or stent thrombosis. Always coordinate any change with Dr. Kedan.
How do I start antiplatelet therapy with Dr. Kedan?
Schedule a consultation at the Beverly Hills office with prior cardiovascular records, procedure reports, and a current medication list. Cardiolucent is a concierge practice and does not bill Medicare or insurance, though a detailed superbill is provided for out-of-network reimbursement. Call (310) 304-5555 or use the contact form.

Explore

Related Treatments

Optimizing antiplatelet therapy?

Discuss this treatment with Dr. Kedan in Beverly Hills.
Schedule an Appointment

Medical Disclaimer

The information on this site is for general educational purposes only and is not medical advice, diagnosis, or treatment. Reading this site does not create a doctor–patient relationship. Always consult a qualified healthcare professional for personal guidance. If this is an emergency, call 911. Mentions of medications, devices, or procedures are informational and not endorsements. Full medical disclaimer.

†Some listed indications involve investigational/off-label use. Learn more.